Machine Learning-Driven QSAR Modeling of FXIa Inhibitors for Virtual Screening and Rational Drug Design
Pharmaceuticals · 10.06.2026 · 19 (6) · 912
DOI: 10.3390/ph19060912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 10.06.2026. Verfasst von Ali Onur Kaya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy Department, Health Services Vocational School, Akdeniz University, 07070 Antalya, Türkiye. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Coagulation factor XIa (FXIa) has emerged as a promising therapeutic target for the development of safer anticoagulant therapies with reduced bleeding risk. This study aimed to develop an interpretable machine learning-driven quantitative structure–activity relationship (QSAR) framework for predicting the inhibitory activity of FXIa inhibitors and supporting virtual screening applications.
Methods
A total of 3026 curated compounds retrieved from the ChEMBL database were used for regression modeling, whereas 2119 compounds were retained for classification modeling after excluding intermediate-activity molecules. Molecular descriptors were generated using RDKit, Mordred, and Morgan fingerprint representations. Following preprocessing and feature selection, multiple machine learning algorithms were systematically benchmarked. Model robustness and reliability were further evaluated using 5-fold cross-validation, scaffold-aware validation, applicability domain analysis, and Y-randomization testing.
Results
Nonlinear ensemble learning approaches consistently outperformed conventional linear algorithms. The optimized HistGradientBoostingRegressor achieved the best regression performance, with an independent test-set R2 value of 0.711 and an RMSE value of 0.759, whereas the optimized classification model achieved accuracies approaching 95%. SHAP analysis identified lipophilicity-related descriptors, aromatic scaffold organization, electrostatic surface properties, and molecular topology as major contributors to FXIa inhibitory activity prediction. In addition, a proof-of-concept virtual screening workflow successfully identified several candidate compounds exhibiting high predicted pKi values and elevated active-class probabilities.
Conclusions
The proposed framework provides a robust, interpretable, and reproducible machine learning-driven QSAR strategy for FXIa inhibitor discovery and may facilitate future virtual screening campaigns and medicinal chemistry optimization studies targeting FXIa-associated anticoagulant drug discovery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiotherapy Department, Health Services Vocational School, Akdeniz University, 07070 Antalya, Türkiye.
- Motor Vehicles Department, Sorgun Vocational School, Yozgat Bozok University, 66000 Yozgat, Türkiye.
- Department of Mathematics and Science Education, Faculty of Education, Akdeniz University, 07070 Antalya, Türkiye.
ORCID-Profile: Ali Onur Kaya, Mert Can Emre
Zitieren
APA
Kaya, A. O., Emre, M. C., & Emre, N. (2026). Machine Learning-Driven QSAR Modeling of FXIa Inhibitors for Virtual Screening and Rational Drug Design. Pharmaceuticals, 19(6), 912. https://doi.org/10.3390/ph19060912
Vancouver
Kaya AO, Emre MC, Emre N. Machine Learning-Driven QSAR Modeling of FXIa Inhibitors for Virtual Screening and Rational Drug Design. Pharmaceuticals. 2026;19(6):912. doi:10.3390/ph19060912
BibTeX
@article{Kaya2026,
author = {Kaya, Ali Onur and Emre, Mert Can and Emre, Nesrin},
title = {Machine Learning-Driven QSAR Modeling of FXIa Inhibitors for Virtual Screening and Rational Drug Design},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {912},
doi = {10.3390/ph19060912}
}
EUVIMED